Polarean Imaging plc (AIM: POLX) - New System Order with the University of British Columbia

Polarean Imaging plc (AIM: POLX), the medical imaging technology company, with a proprietary drug device combination product for the magnetic resonance imaging (MRI) market, announces that it has entered into a contract for the procurement of its latest polarizer system by the University of British Columbia www.ubc.ca  (“UBC”) following the conclusion of UBC’s procurement process.

UBC have received financial support from the Canada Foundation for Innovation (“CFI”) www.innovation.ca/about. CFI have also been active in supporting pulmonary imaging research using hyperpolarized ¹²⁹Xe in the Toronto area and specifically, the SickKids Hospital in Toronto.

Richard Hullihen, CEO of Polarean, said: "We are excited to welcome Drs. Sin and Leipsic and the staff of UBC to our expanding base of collaborative researchers and look forward to assisting them in achieving the goals of their research programme. UBC has a long history and pioneering reputation in the field of medical imaging research and I look forward to providing further updates regarding our collaboration with UBC as appropriate.

“The Company’s management team is excited to see the continued scientific and clinical evolution of hyperpolarized xenon imaging in medicine and to assist in providing our equipment to researchers in order to push these important frontiers.”

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries: